‘‘(i) the provisions of this subsection that apply 
to research with a controlled substance in the appli-
cable schedule shall apply to research with mari-
juana or that compound, as applicable; and 
‘‘(ii) subparagraphs (A) through (G) of this 
paragraph shall not apply to research with mari-
juana or that compound, as applicable.’’. 
(b) CONFORMING AMENDMENT.—Section 102(16) of 
the Controlled Substances Act (21 U.S.C. 802(16)) is 
amended by inserting ‘‘or ‘marijuana’ ’’ after ‘‘The term 
‘marihuana’ ’’. 
SEC. 3. MANUFACTURING OF MARIJUANA FOR CLINICAL 
USE. 
Section 303 of the Controlled Substances Act (21 
U.S.C. 823) is amended by adding at the end the fol-
lowing: 
‘‘(k) REGISTRATION OF PERSONS TO MANUFACTURE 
AND DISTRIBUTE MARIJUANA.— 
‘‘(1) MANUFACTURE
AND
DISTRIBUTION
FOR 
USE IN RESEARCH.—The Attorney General shall reg-
ister an applicant to manufacture or distribute mari-
juana on behalf of the Federal Government to the 
extent that the marijuana is intended to be used ex-
clusively for legitimate research and scientific uses, 
in accordance with the applicable requirements 
VerDate Sep 11 2014 
05:13 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H4825.IH
H4825
SSpencer on DSKBBXCHB2PROD with BILLS
under subsection (a) or (b) for registration of manu-
facturers or distributors of controlled substances in 
schedule I or II. 
‘‘(2) MANUFACTURE
AND
DISTRIBUTION
FOR 
COMMERCIAL
PRODUCTION
OF
FDA-APPROVED 
DRUGS.—The Attorney General shall register an ap-
plicant to manufacture or distribute marijuana on 
behalf of the Federal Government exclusively for the 
purpose of commercial production of a drug con-
taining or derived from marijuana that is approved 
by the Secretary under section 505 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355), in 
accordance with the applicable requirements under 
subsection (a) or (b) of this section for registration 
of manufacturers or distributors of controlled sub-
stances in schedule I or II. 
‘‘(3) NO LIMIT ON NUMBER OF MANUFACTUR-
ERS
AND
DISTRIBUTORS.—The Attorney General 
shall not impose a limit on the number of applicants 
eligible to be registered under paragraph (1) or (2). 
‘‘(4) TIMING.—Not later than 30 days after the 
date on which the Attorney General receives an ap-
plication for registration under paragraph (1) or (2), 
the Attorney General shall— 
‘‘(A) grant the application; or 
VerDate Sep 11 2014 
05:13 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4825.IH
H4825
SSpencer on DSKBBXCHB2PROD with BILLS
‘‘(B) serve an order to show cause upon 
the applicant in accordance with section 304(c). 
‘‘(5) DETERMINATION OF SUPPLY.—In consid-
ering the factors under subsection (a) or (b), as ap-
plicable, for the purposes of registering an applicant 
eligible under paragraph (1) or (2) of this sub-
section, the Attorney General shall consider the de-
mand from researchers for an adequate and uninter-
rupted supply of specific strains of marijuana and 
for marijuana grown pursuant to specific manufac-
turing processes. 
‘‘(6) RELATION TO THE SINGLE CONVENTION 
ON NARCOTIC DRUGS.— 
‘‘(A) CONSTRUCTIVE
POSSESSION
AND 
CONTROL.—The registration of manufacturers 
and distributors of marijuana under paragraphs 
(1) and (2) shall constitute constructive posses-
sion and control by the Federal Government for 
the purposes of the obligations under the Single 
Convention on Narcotic Drugs. 
‘‘(B) ARTICLE 28.—Article 28 of the Sin-
gle Convention on Narcotic Drugs shall not be 
construed to prohibit, or impose additional re-
strictions upon, the manufacturing of mari-
juana that is conducted in accordance with 
VerDate Sep 11 2014 
05:13 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H4825.IH
H4825
SSpencer on DSKBBXCHB2PROD with BILLS
paragraph (1) or (2), as applicable, and other 
applicable provisions of this title.’’. 
SEC. 4. GOOD MANUFACTURING PRACTICES. 
Not later than 180 days after the date of enactment 
of this Act, the National Institute for Drug Abuse shall 
develop and publish recommendations for good manufac-
turing practices for growing and producing marijuana (as 
defined in section 102 of the Controlled Substance Act (21 
U.S.C. 802), as amended by this Act) for research. 
SEC. 5. QUOTAS. 
Section 306(e) of the Controlled Substances Act (21 
U.S.C. 826(e)) is amended in the third sentence by strik-
ing ‘‘exceeds the aggregate of the quotas of all registrants 
under this section’’ and inserting ‘‘should be increased to 
meet the changing medical, scientific, and industrial needs 
for the controlled substance’’. 
SEC. 6. TERMINATION OF INTERDISCIPLINARY REVIEW 
PROCESS FOR NON-NIH-FUNDED RESEARCH-
ERS. 
The Secretary of Health and Human Services may 
not— 
(1) reinstate the Public Health Service inter-
disciplinary review process described in the guidance 
entitled ‘‘Guidance on Procedures for the Provision 
VerDate Sep 11 2014 
05:13 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H4825.IH
H4825
SSpencer on DSKBBXCHB2PROD with BILLS
of Marijuana for Medical Research’’ (issued on May 
21, 1999); or 
(2) create an additional review of scientific pro-
tocols that is conducted only for research on mari-
juana (as defined in section 102 of the Controlled 
Substances Act (21 U.S.C. 802), as amended by sec-
tion 2(b)) other than the review of research proto-
cols performed at the request of a researcher con-
ducting nonhuman research that is not federally 
funded, 
in 
accordance 
with 
section 
303(f)(3)(A)(ii)(II) of the Controlled Substances Act 
(21 U.S.C. 823(f)(3)(A)(ii)(II)), as amended by sec-
tion 2(a). 
Æ 
VerDate Sep 11 2014 
05:13 Jan 20, 2018
Jkt 079200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6301
E:\BILLS\H4825.IH
H4825
SSpencer on DSKBBXCHB2PROD with BILLS